RE: Timing16 Dec 2023 13:37
It should but things can change and any technical issues or patient reactions for other reasons will always make this timeline that may extend given the human factor.
I think this is actually a masterstroke to get c7 finished and Phase 2 started with potentially more cohorts and a bigger chance of many remissions with a big reduction in tumour size.
Like some. Last Weds I was a little disappointed but the following is now evident and possible.
*Smaller runway at a vastly reduced cost
* Ava 6000 self owned and an avacta product held internally
* More cohorts.
*Less time
* More results which by the way could be spectacular on current data records
So although Weds and the market reaction is a dampener, looking longer term this could be an hidden gem of a move.
Add into that not mix
3996 JV and partnership.
Other chemo type via the Avacta war head and then the big ADC potential then we are like a super volcano that will erupt at some point with explosive effects.
Stay safe all.
LTH